CCL2 and ovarian carcinoma: With the exception of a few publications on cervical and ovarian cancers [16, 17], which showed a correlation between MCP-1 systemic levels and cancer progression, no studies have evaluated MCP-1 serum levels in correlation with PDA risk factors, such as obesity.